Long-term use of anti-anxiety drugs continues in B.C. despite known health risks: study

May 20, 2010

Drugs to treat anxiety and sleep disorders are still being prescribed for extended periods to British Columbian patients - and increasingly so for baby boomers - despite warnings against long-term use, according to a University of British Columbia study.

Published online in the journal , the study by researchers at UBC's Centre for Health Services and Policy Research (CHSPR) is the first of its kind to examine the use of benzodiazepines such as Xanax and Ativan for an entire population over time. It's also the first to pinpoint the socio-economic characteristics associated with long-term users of such drugs.

Results show that seniors and low-income earners are more likely to be long-term users of benzodiazepines, with rates remaining steady over a 10-year period. Meanwhile, use among the middle-aged population has increased. Harms associated with long-term use (more than 100 days in a year) can include dependence and tolerance, , and increased risks of falls in the elderly.

"Given the potential for dependence and harms associated with these drugs, they are recommended to be used sparingly for short periods," says Colleen Cunningham, CHSPR researcher and lead author of the study. "However, our study suggests that a significant number of British Columbians - especially the elderly who suffer greater health risks from falls - are using them for long periods."

Benzodiazepines are one of the most commonly prescribed types of neurological drugs in developed countries. The UBC study compared health records of B.C. residents from 1996 and 2006. Of the 4.9 per cent of the overall B.C. population who were given short-term benzodiazepine prescriptions in 2006 and 3.5 per cent who were given long-term prescriptions:

  • Nearly half of long-term users were over age 65, and more than a quarter were 75 or older
  • Two out of three were women, both for short- and long-term use
  • Long-term users were more likely to be in the lowest income bracket than short-term or non-users
Cunningham and co-authors Gillian Hanley and Steve Morgan found long-term use in 2006 was associated with early use - half of all 2006 long-term users had been prescribed benzodiazepines in 1996. The researchers are calling for prescribing practices and policies that target populations younger than conventionally studied (i.e. under age 65) to reduce rates of long-term use.

Explore further: Added benefit of vedolizumab is not proven

add to favorites email to friend print save as pdf

Related Stories

Sedatives, mood-altering drugs related to falls among elderly

Nov 23, 2009

Falls among elderly people are significantly associated with several classes of drugs, including sedatives often prescribed as sleep aids and medications used to treat mood disorders, according to a study led by a University ...

Recommended for you

Added benefit of vedolizumab is not proven

5 hours ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0